콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

5.31465

Sigma-Aldrich

Val-boroPro

≥98% (HPLC), solid, DPP-IV, DPP8 and DPP9 inhibitor, Calbiochem®

동의어(들):

Val-boroPro, PT-100, Talabostat, H₂N-( S)-Val-( R)-boroPro-OH, CH₃SO₃H, H-( S)-Val-( R)-boroPro-OH, CH₃SO₃H, Valinyl-L-boroproline, CH₃SO₃H, DPP Inhibitor

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C10H23BN2O6S
CAS Number:
Molecular Weight:
310.18
MDL number:
UNSPSC 코드:
12352200
NACRES:
NA.77

제품명

Val-boroPro,

분석

≥98% (HPLC)

Quality Level

양식

solid

효능

180 pM Ki

제조업체/상표

Calbiochem®

저장 조건

OK to freeze
desiccated (hygroscopic)
protect from light

색상

light beige

solubility

DMSO: 100 mg/mL

저장 온도

2-8°C

SMILES string

B(O)(O)[C@H]1N(CCC1)C(=O)[C@@H]([N+H3])C(C)C.[S](=O)(=O)([O-])C

InChI

1S/C9H19BN2O3.CH4O3S/c1-6(2)8(11)9(13)12-5-3-4-7(12)10(14)15;1-5(2,3)4/h6-8,14-15H,3-5,11H2,1-2H3;1H3,(H,2,3,4)/t7-,8-;/m0./s1

InChI key

OXYYOEIGQRXGPI-WSZWBAFRSA-N

일반 설명

A prolineboronic acid-based broad-spectrum DDP IV activity and/or structural homologue (DASH) family dipeptidyl peptidases inhibitor that converts in solution between the protonated active form and a cyclized inactive form due to a reversible intramolecular B-N dative bond formation of the non-protonated Val-boroPro (kinact = 6.4 x 10--4 s- and kcyc = 6.4 x 10-5 s- at pH 7.8). Although equilibrium favors cyclization at basic pH, high affinity binding (kon & koff toward CD26 at pH 7.8 = 5.02 x 106 M-s- and 77.8 x 10-6 s-, respectively) drives the equilibrium away from cyclization and traps the active form in enzyme-bound state with prolonged incubation. Reported to inhibit DPP7/DPPII/QPP (IC50/[Substrate]/rxn time at pH 5.5 = 15 nM/500 µM Lys-Pro-MNA/1 h & 310 nM/50 µM Nle-Pro-AMC/15 min), CD26/DPPIV (IC50 = 26 nM; 500 µM Ala-Pro-MNA for 1 h at pH 7.8), fibroblast activation protein/FAP (IC50 = 40 nM; 250 µM Ala-Pro-AFC at pH 2.0), DPP8 (IC50 = 4 nM; 100 µM Ala-Pro-AFC for 15 min at pH 8.0), DDP9 (IC50 = 11 nM; 100 µM Gly-Pro-AMC for 30 min at pH 7.4) with little potency against 9 other proteases (IC50 >100 µM; aminopeptidase P, chymoptrypsin, leukocyte elastase, plasma kallikrein, plasmin, prolidase, thrombin, trypsin, tryptase), while contradictory reports regarding prolyl endopeptidase/PEP/PREP inhibition exist (e.g. IC50 = 390 nM/50 µM Z-Gly-Pro-AMC/pH 7.5/30 min vs. 25 µM/500 µM Z-Gly-Pro-MNA/pH 7.8/60 min). Shown to promote the propagation of human BM CD34+ cells by stimulating stromal cells cytokine production in vitro (min EC 0.1 nM) and display hematopoietic stimulatory effect in mice in vivo (min ED 2 µg/mouse/12 h; p.o.). Although orally available in mice and rats, caution must be taken not to exceed toxicity levels (MTD = 25 µg/mL using Sprague-Dawley rats; LD50 ~0.5 mg/mL in 24 survival test using Fisher rats; p.o.) for in vivo studies.
An orally available amino boronic acid dipeptide with antihyperglycemic and anticancer properties. Acts as a highly potent, reversible, and transition state analog inhibitor of dipeptidyl peptidase IV (DPP-IV; IC50 = 26 nM; Ki = 180 pM). Also inhibits the activity of other prolyl peptidases (IC50 = 15 nM for DPP-II; and Ki = 1.5 nM and 760 pM for DPP8 and DPP9, respectively) and at much higher concentrations affects the activities of quiescent cell proline dipeptidase (QPP, DPP7; IC50 = 310 nM), PEP (IC50 = 390 nM) and fibroblast activation protein (FAP; IC50 = 560 nM). However, it does not inhibit the activity of trypsin, chymoptrypsin, thrombin, plasmin, tryptase, leukocyte elastase, and plasma kallikrein even at high levels (~100 µM). Promotes hematopoiesis and the growth of primitive hematopoietic progenitor cells by increasing the production of G-CSF, IL-6, and IL-11 by bone marrow stromal cells in mice. Although it has no direct cytotoxic effect on tumors in vitro, but oral administration in mice is shown to reduce the growth of syngeneic tumors derived from fibrosarcoma (WEHI164), lymphoma (EL4 and A20/2J), melanoma (B16-F10), and mastocytoma (P815) cell lines and augments antibody-dependent cell-mediated cytotoxicity. Note: In aqueous physiological solutions, it can cyclize in a time-dependent manner causing a 100-fold diminution in its inhibitory potency. However, at lower pH range it remains in an active open chain form. Maximum tolerated dose in mice or rats is ~ 25 µg/kg.

Please note that the molecular weight for this compound is batch-specific due to variable water content.

생화학적/생리학적 작용

Cell permeable: yes
Primary Target
DPP-IV, DPP8 and DPP9
Reversible: yes
Secondary Target
QPP, PEP and FAP
Target IC50: 15 nM for DPP-II

포장

Packaged under inert gas

경고

Toxicity: Standard Handling (A)

재구성

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Use only fresh DMSO for reconstitution.

기타 정보

Poplawski, S.E., et al. 2011, J. Med. Chem.54, 2022.
Connolly, B.A., et al. 2008. J. Med. Chem.51, 6005.
Lankas, G.R., et al. 2005. Diabetes54, 2988.

Cheng, J.D., et al. 2005. Mol. Cancer Ther.4, 351.
Adams, S., et al. 2004. Cancer Res.64, 5471.
Jones, B., et al. 2003. Blood102, 1641.
Coutts, S.J., et al. 1996. J. Med. Chem.39, 2087.
Snow, R.J., et al. 1994. J. Am. Chem. Soc.116, 10860.
Kelly, T.A., et al. 1993. J. Am. Chem. Soc.115, 12637.

법적 정보

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable


시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Jonathan D Cheng et al.
Molecular cancer therapeutics, 4(3), 351-360 (2005-03-16)
Tumor-associated fibroblasts are functionally and phenotypically distinct from normal fibroblasts that are not in the tumor microenvironment. Fibroblast activation protein is a 95 kDa cell surface glycoprotein expressed by tumor stromal fibroblasts, and has been shown to have dipeptidyl peptidase
Sharlene Adams et al.
Cancer research, 64(15), 5471-5480 (2004-08-04)
The amino boronic dipeptide, PT-100 (Val-boro-Pro), a dipeptidyl peptidase (DPP) inhibitor, has been shown to up-regulate gene expression of certain cytokines in hematopoietic tissue via a high-affinity interaction, which appears to involve fibroblast activation protein. Because fibroblast activation protein is
George R Lankas et al.
Diabetes, 54(10), 2988-2994 (2005-09-28)
Dipeptidyl peptidase (DPP)-IV inhibitors are a new approach to the treatment of type 2 diabetes. DPP-IV is a member of a family of serine peptidases that includes quiescent cell proline dipeptidase (QPP), DPP8, and DPP9; DPP-IV is a key regulator
S J Coutts et al.
Journal of medicinal chemistry, 39(10), 2087-2094 (1996-05-10)
A series of prolineboronic acid (boroPro) containing dipeptides were synthesized and assayed for their ability to inhibit the serine protease dipeptidyl peptidase IV (DPPIV). Inhibitory activity, which requires the (R)-stereoisomer of boroPro in the P1 position, appears to tolerate a
Beth A Connolly et al.
Journal of medicinal chemistry, 51(19), 6005-6013 (2008-09-12)
Dipeptidyl peptidase IV (DPP-IV; E.C. 3.4.14.5), a serine protease that degrades the incretin hormones GLP-1 and GIP, is now a validated target for the treatment of type 2 diabetes. Dipeptide boronic acids, among the first, and still among the most

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.